OUR PIPELINE
NanOâ‚‚ has completed Phase Ib/IIa clinical trials in acute ischemic stroke and glioblastoma.
See Publications to learn more.
S1 Clinical Programs
Phase III
Pre-clinical
Phase Ib/IIa
Phase IIb
Indication
ACUTE ISCHEMIA
ONCOLOGY
Stroke*, ***
ARDS
Glioblastoma*,**
Funding Partner:
Funding Partners:
Funding Partner:
*IND Allowed for Phase IIb trial
**Orphan Drug Designation Granted
***Investigator Initiated Trial
Completed
In Progress
S1 Pre-Clinical Programs
OTHER
IND Enabling
Early Discovery
Late Discovery
Lead Optimization
Indication
ACUTE ISCHEMIA
ONCOLOGY
Cardiac Arrest
Traumatic Brain Injury
Sickle Cell Disease
Immunotherapy Breast Cancer
Funding Partner:
Funding Partner:
Funding Partner:
Funding Partner:
IND
**: Orphan Drug Designation granted
Completed
In Progress
A New Paradigm in Oxygen Delivery
NuvOx’s discovery of NanOâ‚‚ derives from Dr. Unger’s pioneering work in microbubbles. Dr. Unger’s first company, ImaRx Pharmaceutical, developed a leading microbubble product, now sold as Definity®, an ultrasound contrast agent.
The active pharmaceutical ingredient in microbubbles is a class of compounds called perfluorocarbons, which have been studied for their ability to carry oxygen. Earlier versions had high boiling points, making them less effective.
​
Our key ingredient, Dodecafluoropentane emulsion (DDFPe), has a low boiling point of 29°C, meaning it transitions from liquid to gas at body temperature. Injected as tiny liquid droplets, it naturally turns into gas bubbles that carry 1,000 times more oxygen than the liquid form, making it an exceptional oxygen delivery system.​
​
Originally developed as an ultrasound contrast agent, DDFPe never launched commercially but has proven stable when stored as a refrigerated liquid nanoemulsion.
​
​Recognizing the potential of DDFPe to deliver far more oxygen than previous perfluorocarbons, the Company licensed the patents and obtained ownership of the regulatory documents for DDFPe and launched the program to develop NanO₂ .
Multiple studies both clinical and pre-clinical have shown that NanOâ‚‚ improves the flow of oxygen between blood and tissue and have demonstrated the potential of NanOâ‚‚ to improve oxygen delivery at significantly lower doses compared to prior perfluorocarbons. NanOâ‚‚ has the potential to represent a new paradigm in oxygen delivery
NanOâ‚‚ is under clinical investigation and not yet approved for general medical use.
Consistent Results
NanOâ‚‚ 's unique mechanism of action allows it to improve the flow of oxygen from lungs to blood and from blood to tissue. Over 30 animal studies have shown therapeutic effect in seven different indications where hypoxia is life threatening.